A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
Riillo C, Polerà N, Di Martino MT, Juli G, Hokanson CA, Odineca T, Signorelli S, Grillone K, Ascrizzi S, Mancuso A, Staropoli N, Caparello B, Cerra M, Nisticò G, Tagliaferri P, Crea R, Caracciolo D, Tassone P.
Riillo C, et al. Among authors: crea r.
J Transl Med. 2023 May 4;21(1):301. doi: 10.1186/s12967-023-04101-x.
J Transl Med. 2023.
PMID: 37143061
Free PMC article.